|
2024
|
Invention
|
Process for the synthesis of 6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetr... |
|
|
Invention
|
Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]... |
|
2023
|
Invention
|
Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inh... |
|
2022
|
P/S
|
Pharmaceuticals Research and development services in the pharmaceutical field; clinical trials i... |
|
|
P/S
|
Pharmaceuticals. Research and development services in the pharmaceutical field; clinical trials i... |
|
2021
|
Invention
|
Pde9 inhibitors for treating thalassemia.
The present disclosure relates to PDE9 inhibitors, com... |
|
|
Invention
|
Pde9 inhibitors for treating cardiac failure.
The present disclosure relates to PDE9 inhibitors,... |
|
|
Invention
|
Pde9 inhibitors for treating cardiac failure. The present disclosure relates to PDE9 inhibitors, ... |
|
|
Invention
|
Pde9 inhibitors for treating sickle cell disease.
The present disclosure relates to PDE9 inhibit... |
|
|
Invention
|
Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as camkii inhibitors.... |
|
|
Invention
|
Fused heteroaryl compounds and their use as camkii inhibitors. The present invention provides a f... |
|
2020
|
Invention
|
Pde9 inhibitors for treatment of peripheral diseases.
The present invention relates to PDE9 inhi... |
|
|
Invention
|
Pde9 inhibitors for treating sickle cell disease. The present disclosure relates to PDE9 inhibito... |
|
2018
|
Invention
|
Process for the synthesis of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetra... |
|
|
Invention
|
Methods of making and using pde9 inhibitors. The present invention relates to PDE9 inhibitors, th... |
|
2016
|
P/S
|
Research and development in the pharmaceutical field; conducting clinical trials for others in th... |
